18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma

Cancer

Volumn 79, Issue 1, 1997, Pages 115-126

  Barker II, Fred G ^a,b   Chang, Susan M ^a   Valk, Peter E ^c   Pounds, Thomas R ^c   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Northern California PET Imaging Ctr   (United States)

Author keywords

18 fluorodeoxyglucose positron emission tomography; glucose uptake; malignant glioma; prognostic factors; recurrence; survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; GLIOBLASTOMA; GLUCOSE TRANSPORT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION NECROSIS; RECURRENT CANCER; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0031016159     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970101)79:1<115::AID-CNCR17>3.0.CO;2-7     Document Type: Article

References (70)

1. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992;10:766-71.
2. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas:results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-88.
3. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994;19:69-74.
4. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol 1991;12:45-62.
5. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions:MR imaging. Radiology 1986;158:149-55.
6. Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP, et al. Radiation necrosis or glioma recurrences:is computer-assisted stereotactic biopsy useful? J Neurosurg 1995;82:436-44.
7. Cascino TL, Kimmel DW, Dinapoli RP, O'Neill BP, Scheithauer B. Report of four cases with a resolving syndrome which otherwise simulates recurrent brain tumor [abstract]. Neurology 1988;38(Suppl 1):306.
8. Gutin PH. Treatment of radiation necrosis of the brain. In: Gutin PH, Leibel SA, Sheline GE, editors. Radiation injury to the nervous system. New York:Raven Press, 1991:271-82.
9. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
10. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
11. Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S. Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28-33.
12. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-8.
13. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
14. Padgett HC, Schmidt DG, Luxen A, Bida GT, Satyamurthy N, Barrio JR. Computer-controlled radiochemical synthesis:a chemistry process control unit for the automated production of radiochemicals. Int J Radiat Appl Instrum [A] 1989;40:433-45.
15. Lee ET. Statistical methods for survival data analysis. New York:John Wiley & Sons, 1992.
16. Cox DR. Regression models and life tables. J R Stat Soc [Ser B] 1972;34:187-220.
17. Agresti A. Categorical data analysis. New York:John Wiley & Sons, 1990.
18. Sprent P. Applied nonparametric statistical methods. London:Chapman & Hall, 1993.
19. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours:is it useful? J Neurol Neurosurg Psychiatry 1995;57:250-2.
20. Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC, Schold SC, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796-801.
21. Levivier M, Goldman S, Bidaut LM, Luxen A, Stanus E, Przedborski S, et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992;31:792-7.
22. Levivier M, Goldman S, Pirotte B, Brucher J-M, Balériaux D, Luxen A, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]-fluorodeoxyglucose. J Neurosurg 1995;82:445-52.
23. Maciunas RJ, Kessler RM, Maurer C, Mandava V, Watt G, Smith G. Positron emission tomography imaging-directed stereotactic neurosurgery. Stereotact Funct Neurosurg 1992; 58:134-40.
24. Black KL, Emerick T, Hoh C, Hawkins RA, Mazziotta J, Becker DP. Thallium-201 SPECT and positron emission tomography equal predictors of glioma grade and recurrence. Neurol Res 1994;16:93-6.
25. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.
26. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-71.
27. Tyler JL, Diksic M, Villemure J-G, Evans AC, Meyer E, Yamamoto YL, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123-33.
28. Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79:853-8.
29. Davis WK, Boyko OB, Hoffman JM, Hanson MW, Schold SC Jr Burger PC, et al. [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol 1993;14:515-23.
30. Go KG, Kamman RL, Mooyaart EL, Heesters MA, Pruim J, Vaalburg W, et al. Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology 1995; 37:198-206.
31. Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J, et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992;31:319-27.
32. Kessler RM, Maciunas R, Eisert D, Moots P, Smith G. PET FDG studies in early delayed radiation necrosis following cerebral stereotactic radiosurgery [abstract]. J Nucl Med 1993;34:206P.
33. Lau YH, Wang G-J, Volkow ND, Fowler JS, Meek AG, Park TL, et al. Determination of glucose metabolism of brain tumors and adjacent normal brain tissue and their early response to radiotherapy by F-18 fluorodeoxyglucose positron emission tomography [abstract]. Int J Radiat Oncol Biol Phys 1994;30(Suppl 1):296.
34. Rozental JM, Levine RL, Mehta MP, Kinsella TJ, Levin AB, Algan O, et al. Early changes in tumor metabolism after treatment:the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1991;20:1053-60.
35. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 1993;15:57-66.
36. Rozental JM, Levine RL, Nickles RJ. Changes in glucose uptake by malignant gliomas:preliminary study of prognostic significance. J Neurooncol 1991;10:75-83.
37. Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989;46:1302-7.
38. Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989;24:1-5.
39. Holzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993;17:681-7.
40. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, et al. Cerebral necrosis after radiotherapy and/ or intraarterial chemotherapy for brain tumors:PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189-97.
41. Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recur-rence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11:563-70.
42. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, et al. Diagnosis of recurrent brain tumor:value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994;163:1459-65.
43. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;32:197-202.
44. Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, et al. Work in progress:[18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982;144:885-9.
45. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988;69:830-8.
46. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074-8.
47. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991;10:85-91.
48. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994;73:2386-94.
49. Schifter T, Hoffman JM, Hanson MW, Boyko OB, Beam C, Paine S, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993;17:509-16.
50. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994;74:2836-42.
51. Wolfe RA, Strawderman RL. Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 1996;27:124-9.
52. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies:examples from the AIDS literature. Ann Intern Med 1996;124:999-1005.
53. Barker FG II. Analysis of the relationship between long-term operative success and a transient or delayed operative side effect. Neurosurgery 1996;39:412-6.
54. Shrieve DC, Alexander E III, Wen PY, Fine HA, Kooy HM, Black PM, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36:275-84.
55. Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. Linac radiosurgery for high-grade gliomas:the University of Florida experience. Int J Radiat Oncol Biol Phys 1995; 32:205-10.
56. Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989;71:342-6.
57. Oriuchi N, Tamura M, Shibazaki T, Ohye C, Watanabe N, Tateno M, et al. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas:relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 1993; 34:2085-9.
58. Slizofski WJ, Krishna L, Katsetos CD, Black P, Miyamoto C, Brown SJ, et al. Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. Cancer 1994;74:3190-7.
59. Carvalho PA, Schwartz RB, Alexander E III, Garada BM, Zimmerman RE, Loeffler JS, et al. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992;77:565-70.
60. Kosuda S, Fujii H, Aoki S, Suzuki K, Tanaka Y, Nakamura O, et al. Prediction of survival in patients with suspected recurrent cerebral tumors by quantitative thallium-201 single photon emission computed tomography. Int J Radiat Oncol Biol Phys 1994;30:1201-6.
61. Schwartz RB, Carvalho PA, Alexander E III, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma:differentiation by using dual-isotope SPECT with 201T1 and 99mTc-HMPAO. AJR Am J Roentgenol 1992;158:399-404.
62. Vertosick FT Jr., Selker RG, Grossman SJ, Joyce JM. Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 1994;34:396-401.
63. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995;36:159-64.
64. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, et al. Clinical evaluation of thallium-201 SPECT for the detection and differentiation of gliomas:a comparative study with C-11 methionine and F-18 FDG PET [abstract]. J Nucl Med 1994;35:43P.
65. Wong FCL, Garcia JR, Yung WKA, Kim EE, Levin VA, Leeds NE, et al. Comparison of thallium-201 SPECT and F-18 fluorodeoxyglucose PET in the evaluation of MRI lesions in patients with gliomas after therapy [abstract]. J Nucl Med 1994;35:220P.
66. Kingsley DP, Kendall BE. CT of the adverse effects of therapeutic radiation of the central nervous system. AJNR Am J Neuroradiol 1981;2:453-60.
67. van Dellen JR, Danziger A. Failure of computerized tomography to differentiate between radiation necrosis and cerebral tumour. S Afr Med J 1978;53:171-2.
68. Go KG, Keuter EJ, Kamman RL, Pruim J, Metzemaekers JD, Staal MJ, et al. Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994;34:994-1002.
69. Preul MC, Caramanos Z, Collins DL, Villemure J-G, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-5.
70. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, et al. Cerebral blood volume maps of gliomas:comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.